Synbiotic capsules reduced urinary oxalate significantly (P=.001) vs placebo over 12 weeks, but left all other stone-risk markers unchanged.
Journal: Urology Journal | Published: 2026-05-29 | Type: Randomized Controlled Trial | PMID: 41255037 Authors: Maddahi N, Zamani B, Nadjarzadeh A, Basiri A, Tabibi H, Kashefi M, Tabatabai SA — Iranian institutions including Shahid Sadoughi University of Medical Sciences and Mashhad University of Medical Sciences Funding/COI: Not listed for either
Forty-four overweight or obese adults with hyperoxaluria were randomized to twice-daily synbiotic capsules or placebo for 12 weeks. Urinary oxalate dropped significantly in the synbiotic group relative to both their own baseline and the placebo group. Every other measured marker — blood and urinary calcium, citrate, uric acid, creatinine, and others — moved the same in both groups. Urine volume increased in both arms, likely reflecting the trial's hydration instructions, not the supplement.
This is a randomized, double-blind, placebo-controlled design — the correct architecture for this question. The sample size of 44 (presumably ~22 per arm) is small. Whether it was powered to detect differences in secondary markers is unknown; the abstract reports no primary/secondary outcome hierarchy, so it is unclear whether the oxalate finding was pre-specified or the most favorable result from a multi-marker fishing expedition. The 12-week window is reasonable for a microbiome intervention but short for assessing kidney stone incidence as a hard endpoint — this study uses surrogate markers only, not actual stone formation or recurrence.
Synbiotics (probiotics + prebiotics) plausibly lower oxalate via gut flora that degrade oxalate, particularly Oxalobacter formigenes, but the paper's abstract does not report which organisms or strains were used, making replication and mechanistic interpretation impossible from this summary alone.
A small, adequately designed RCT showing synbiotics reduce urinary oxalate in a specific high-risk population — that is a genuinely interesting signal, given how limited pharmacological options are for hyperoxaluria short of primary disease management. But 44 patients, an undisclosed synbiotic formulation, and missing funding disclosures make this hypothesis-generating at best. The null results across every other stone-risk marker could mean synbiotics are narrowly targeted to the oxalate pathway, or they could mean the trial was simply too small to detect anything else. Worth watching if a larger follow-up discloses the strain composition and includes recurrence data.